Omada Health (NASDAQ:OMDA) CEO Sean Duffy Sells 21,572 Shares

Omada Health, Inc. (NASDAQ:OMDA) CEO Sean Duffy sold 21,572 shares of the firm’s stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $23.62, for a total value of $509,530.64. Following the completion of the sale, the chief executive officer directly owned 411,861 shares in the company, valued at approximately $9,728,156.82. The trade was a 4.98% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Omada Health Trading Down 4.4%

Shares of OMDA opened at $22.29 on Friday. Omada Health, Inc. has a 12-month low of $10.28 and a 12-month high of $26.92. The company has a market cap of $1.36 billion, a PE ratio of 445.80 and a beta of 1.86. The stock has a 50-day moving average price of $22.66 and a 200-day moving average price of $17.54.

Omada Health (NASDAQ:OMDA) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.08 earnings per share for the quarter, topping the consensus estimate of ($0.02) by $0.10. The company had revenue of $87.83 million for the quarter, compared to analysts’ expectations of $80.93 million. Omada Health had a net margin of 1.39% and a return on equity of 2.60%. As a group, analysts predict that Omada Health, Inc. will post 0.09 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Geode Capital Management LLC purchased a new position in shares of Omada Health during the second quarter worth approximately $637,000. Walleye Capital LLC purchased a new stake in shares of Omada Health in the 2nd quarter valued at $458,000. Ilex Capital Partners UK LLP bought a new position in shares of Omada Health during the 2nd quarter valued at $201,000. Soros Fund Management LLC purchased a new position in Omada Health in the 2nd quarter worth $640,000. Finally, Raymond James Financial Inc. bought a new stake in Omada Health in the second quarter worth $32,000.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. Needham & Company LLC reissued a “buy” rating and issued a $28.00 price target on shares of Omada Health in a report on Friday, May 8th. Robert W. Baird lifted their price objective on shares of Omada Health from $15.00 to $25.00 and gave the stock a “neutral” rating in a report on Wednesday, August 12th. JPMorgan Chase & Co. upped their target price on shares of Omada Health from $26.00 to $30.00 and gave the stock an “overweight” rating in a research report on Friday, August 14th. Morgan Stanley reissued an “overweight” rating and issued a $30.00 target price on shares of Omada Health in a research note on Monday, June 22nd. Finally, BTIG Research raised their price target on Omada Health from $30.00 to $35.00 and gave the company a “buy” rating in a research report on Monday, August 10th. Eleven investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Omada Health presently has an average rating of “Moderate Buy” and an average target price of $26.50.

Omada Health Company Profile

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.